Izun Pharmaceuticals: Developing innovative pharmaceutical products targeting oncology support
Izun Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the rapidly expanding area of oncology support. Our products enable more effective cancer therapy, as well as improve the quality of life for cancer patients.
With the increase in patient-centric medicine, oncology-support therapies are rapidly becoming an integral part of the full spectrum of cancer care and are expected to reach a market size of $22B by 2026.
Izun, with a strong clinical pipeline and an exciting Phase III drug candidate for the prevention of Oral Mucositis, aims to be a leading company in this growing therapeutic area.
Izun Pharmaceuticals utilizes a unique research and development platform to identify novel treatment candidates. Izun identifies drug candidates from natural sources with a strong ethnobotanical safety database and substantial evidence of efficacy. Izun then applies cutting edge pharmacological science to optimize the therapeutic effect, while preserving the fundamental safety, of these potential drugs. This platform has the benefit of developing novel drugs for untapped markets with a greater likelihood of success.
In addition to the benefits of a lower risk profile and an accelerated track to clinical trials, the botanical pathway offers greater protection from generic competition.
To date, Izun has successfully developed several products for multiple therapeutic indications.